Pharmacological induction of CFTR function in patients with cystic fibrosis: Mutation-specific therapy

被引:38
作者
Kerem, E [1 ]
机构
[1] Hadassah Univ Hosp, Dept Pediat, IL-91240 Jerusalem, Israel
[2] Hadassah Univ Hosp, Cystic Fibrosis Ctr, Jerusalem, Israel
关键词
cystic fibrosis; CFTR; pharmacogenetics; mutation-specific therapy; genotype phenotype; CFTR activators; chaperones; aminoglycosides; therapy;
D O I
10.1002/ppul.20200
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
CFTR mutations cause defects of CFTR protein production and function by different molecular mechanisms. Mutations can be classified according to the mechanisms by which they disrupt CFTR function. This understanding of the different molecular mechanisms of CFTR dysfunction provides the scientific basis for the development of targeted drugs for mutation specific therapy of cystic fibrosis (CF). Class I mutations are nonsense mutations that result in the presence of a premature stop codon that leads to the production of unstable mRNA, or the release from the ribosome of a short, truncated protein that is not functional. Aminoglycoside antibiotics can suppress premature termination codons by disrupting translational fidelity and allowing the incorporation of an amino acid, thus permitting translation to continue to the normal termination of the transcript. Class I I mutations cause impairment of CFTR processing and folding in the Golgi. As a result, the mutant CFTR is retained in the endoplasmic reticulum (ER) and eventually targeted for degradation by the quality control mechanisms. Chemical and molecular chaperones such as sodium-4-phenyl butyrate can stabilize protein structure, and allow it to escape from degradation in the ER and be transported to the cell membrane. Class III mutations disrupt the function of the regulatory domain. CFTR is resistant to phosphorylation or adenosine tri-phosphate (ATP) binding. CFTR activators such as alkylxanthines (CPX) and the flavonoid genistein can overcome affected ATIP binding through direct binding to a nucleotide binding fold. In patients carrying class IV mutations, phosphorylation of CFTR results in reduced chloride transport. Increases in the overall cell surface content of these mutants might overcome the relative reduction in conductance. Alternatively, restoring native chloride pore characteristics pharmacologically might be effective. Activators of CFTR at the plasma membrane may function by promoting CFTR phosphorylation, by blocking CFTR dephosphorylation, by interacting directly with CFTR, and/or by modulation of CFTR protein-protein interactions. Class V mutations affect the spicing machinery and generate both aberrantly and correctly spliced transcripts, the levels of which vary among different patients and among different organs of the same patient. Splicing factors that promote exon inclusion or factors that promote exon skipping can promote increases of correctly spliced transcripts, depending on the molecular defect. Inconsistent results were reported regarding the required level of corrected or mutated CFTR that had to be reached in order to achieve normal function.
引用
收藏
页码:183 / 196
页数:14
相关论文
共 109 条
[51]   Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system [J].
Keeling, KM ;
Bedwell, DM .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2002, 80 (06) :367-376
[52]   In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant Delta F508 in murine nasal epithelium [J].
Kelley, TJ ;
Thomas, K ;
Milgram, LJH ;
Drumm, ML .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (06) :2604-2608
[53]   CFTR-MEDIATED CHLORIDE PERMEABILITY IS REGULATED BY TYPE-III PHOSPHODIESTERASES IN AIRWAY EPITHELIAL-CELLS [J].
KELLEY, TJ ;
ALNAKKASH, L ;
DRUMM, ML .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1995, 13 (06) :657-664
[54]   Cystic fibrosis in Jews: Frequency and mutation distribution [J].
Kerem, B ;
Chiba-Falek, O ;
Kerem, E .
GENETIC TESTING, 1997, 1 (01) :35-39
[55]   A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations [J].
Kerem, E ;
RaveHarel, N ;
Augarten, A ;
Madgar, I ;
NissimRafinia, M ;
Yahav, Y ;
Goshen, R ;
Bentur, L ;
Rivlin, J ;
Aviram, M ;
Genem, A ;
ChibaFalek, O ;
Kraemer, MR ;
Simon, A ;
Branski, D ;
Kerem, B .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 155 (06) :1914-1920
[56]  
Kerem E, 1996, PEDIATR PULM, V22, P387, DOI 10.1002/(SICI)1099-0496(199612)22:6<387::AID-PPUL7>3.3.CO
[57]  
2-Y
[58]   INFLUENCE OF CODON CONTEXT ON UGA SUPPRESSION AND READTHROUGH [J].
KOPELOWITZ, J ;
HAMPE, C ;
GOLDMAN, R ;
RECHES, M ;
ENGELBERGKULKA, H .
JOURNAL OF MOLECULAR BIOLOGY, 1992, 225 (02) :261-269
[59]   N-acetyl-L-cysteine and its derivatives activate a Cl- conductance in epithelial cells [J].
Kottgen, M ;
Busch, AE ;
Hug, MJ ;
Greger, R ;
Kunzelmann, K .
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 1996, 431 (04) :549-555
[60]   ATPase activity of the cystic fibrosis transmembrane conductance regulator [J].
Li, CH ;
Ramjeesingh, M ;
Wang, W ;
Garami, E ;
Hewryk, M ;
Lee, D ;
Rommens, JM ;
Galley, K ;
Bear, CE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (45) :28463-28468